Bi Electro

Product NDC: 50066-285
11-digit product format: 500660285
Labeler code: 50066
Product ID: 50066-285_8f09233d-abae-42ae-a76b-3ecf101a2690
Type: HUMAN OTC DRUG
Nonproprietary name: Acetaminophen 250 mg /Aspirin 250 mg/Caffeine 65 mg
Dosage form: TABLET
Route: ORAL
Labeler: Genomma Labs USA, Inc
Application: part343
Marketing category: OTC MONOGRAPH NOT FINAL
Marketing start: 2015-01-08
Marketing end: 0000-00-00
Substance: ACETAMINOPHEN; ASPIRIN; CAFFEINE
Active strength: 250 mg/1; mg/1; mg/1
NDC exclude flag: No
Listing certified through: 2022-12-31
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 2 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Reporting period	Source date
excluded product	product	50066-285		D	Discontinued by firm		2026-10-12
excluded package	package	50066-285	50066-285-24	D	Discontinued by firm		2026-10-12

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 26 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Package NDC	Code	Status	Snapshot	Source SHA-256
2025-12-14 17:58 UTC · source 2025-12-05	excluded product	product		D	Discontinued by firm	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	50066-285-24	D	Discontinued by firm	`d630ba8d3edf…`	`732f749b63fb…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded product	product		D	Discontinued by firm	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	50066-285-24	D	Discontinued by firm	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded product	product		D	Discontinued by firm	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	50066-285-24	D	Discontinued by firm	`2ef7874e63bc…`	`57b86245f4fa…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded product	product		D	Discontinued by firm	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	50066-285-24	D	Discontinued by firm	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded product	product		D	Discontinued by firm	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	50066-285-24	D	Discontinued by firm	`cfe11265f3b6…`	`090c488252e2…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded product	product		D	Discontinued by firm	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	50066-285-24	D	Discontinued by firm	`cdf11ea48f46…`	`ba0047e9e063…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded product	product		D	Discontinued by firm	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	50066-285-24	D	Discontinued by firm	`302b2466d912…`	`e7b80fea0513…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded product	product		D	Discontinued by firm	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	50066-285-24	D	Discontinued by firm	`ed331223b511…`	`672a5bd82f5f…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded product	product		D	Discontinued by firm	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	50066-285-24	D	Discontinued by firm	`0efc9e666f02…`	`f202fb6c5f17…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded product	product		D	Discontinued by firm	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	50066-285-24	D	Discontinued by firm	`ad56d346431e…`	`cc804d4bbf1e…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded product	product		D	Discontinued by firm	`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	50066-285-24	D	Discontinued by firm	`367a005e9d99…`	`383a685ebd0f…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded product	product		D	Discontinued by firm	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	50066-285-24	D	Discontinued by firm	`557ba5c1ecfa…`	`9c80585c8c6e…`
2020-06-10 20:45 UTC · source 2020-06-10	excluded product	product		I	Inactivated by FDA	`9bebd1f3094a…`	`5416666fcb17…`
2020-06-10 20:45 UTC · source 2020-06-10	excluded package	package	50066-285-24	I	Inactivated by FDA	`9bebd1f3094a…`	`5416666fcb17…`

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDC	Effective	Action	Document	Indexing SPL	Related label
50066-285-24	2020-12-03	C162847	48780-1	9d75b9d1-00ba-f424-e053-dadaa90a57ce	Drug Facts
50066-285-24	2020-01-31	C162847	48780-1	9d75b9d1-00ba-f424-e053-dadaa90a57ce	Drug Facts

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
ACETAMINOPHEN	ACTIVE INGREDIENT	362O9ITL9D	BI ELECTRO EXTRA STRENGTH (ACETAMINOPHEN 250 MG /ASPIRIN 250 MG/CAFFEINE 65 MG) TABLET [GENOMMA LAB USA]	1
ASPIRIN	ACTIVE INGREDIENT	R16CO5Y76E	BI ELECTRO EXTRA STRENGTH (ACETAMINOPHEN 250 MG /ASPIRIN 250 MG/CAFFEINE 65 MG) TABLET [GENOMMA LAB USA]	1
CAFFEINE	ACTIVE INGREDIENT	3G6A5W338E	BI ELECTRO EXTRA STRENGTH (ACETAMINOPHEN 250 MG /ASPIRIN 250 MG/CAFFEINE 65 MG) TABLET [GENOMMA LAB USA]	1
ACETAMINOPHEN	ACTIVE MOIETY	362O9ITL9D	BI ELECTRO EXTRA STRENGTH (ACETAMINOPHEN 250 MG /ASPIRIN 250 MG/CAFFEINE 65 MG) TABLET [GENOMMA LAB USA]	1
ASPIRIN	ACTIVE MOIETY	R16CO5Y76E	BI ELECTRO EXTRA STRENGTH (ACETAMINOPHEN 250 MG /ASPIRIN 250 MG/CAFFEINE 65 MG) TABLET [GENOMMA LAB USA]	1
CAFFEINE	ACTIVE MOIETY	3G6A5W338E	BI ELECTRO EXTRA STRENGTH (ACETAMINOPHEN 250 MG /ASPIRIN 250 MG/CAFFEINE 65 MG) TABLET [GENOMMA LAB USA]	1
HYPROMELLOSES	INACTIVE INGREDIENT	3NXW29V3WO	BI ELECTRO EXTRA STRENGTH (ACETAMINOPHEN 250 MG /ASPIRIN 250 MG/CAFFEINE 65 MG) TABLET [GENOMMA LAB USA]	1
POLYETHYLENE GLYCOLS	INACTIVE INGREDIENT	3WJQ0SDW1A	BI ELECTRO EXTRA STRENGTH (ACETAMINOPHEN 250 MG /ASPIRIN 250 MG/CAFFEINE 65 MG) TABLET [GENOMMA LAB USA]	1
STARCH, CORN	INACTIVE INGREDIENT	O8232NY3SJ	BI ELECTRO EXTRA STRENGTH (ACETAMINOPHEN 250 MG /ASPIRIN 250 MG/CAFFEINE 65 MG) TABLET [GENOMMA LAB USA]	1
STEARIC ACID	INACTIVE INGREDIENT	4ELV7Z65AP	BI ELECTRO EXTRA STRENGTH (ACETAMINOPHEN 250 MG /ASPIRIN 250 MG/CAFFEINE 65 MG) TABLET [GENOMMA LAB USA]	1
TITANIUM DIOXIDE	INACTIVE INGREDIENT	15FIX9V2JP	BI ELECTRO EXTRA STRENGTH (ACETAMINOPHEN 250 MG /ASPIRIN 250 MG/CAFFEINE 65 MG) TABLET [GENOMMA LAB USA]	1

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
362O9ITL9D	ACETAMINOPHEN	103-90-2	ACETAMINOPHEN
R16CO5Y76E	ASPIRIN	50-78-2	ASPIRIN
3G6A5W338E	CAFFEINE	58-08-2	CAFFEINE

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Units	Marketing start	Marketing end	Sample	Exclude flag	Status
50066-285-24	50066028524	1 BOTTLE in 1 CARTON (50066-285-24) > 24 TABLET in 1 BOTTLE	1 bottle	2015-01-08	0000-00-00	No	No	Current